Condition: Advanced Malignant Solid Tumors · Sponsor: Hefei Xinzhu Biological Technology Co., Ltd.
This Phase I/II study evaluates the safety, tolerability, and efficacy of N-3C01 administered subcutaneously, both as monotherapy and in combination with a PD-(L)1 monoclonal antibody, in patients with advanced solid tumors. Phase I involves dose escalation for both monotherapy and combination therapy, while Phase II includes cohort expansion for the combination therapy.
This description comes directly from the study's public registry record.
Karen Zhou · +8613521345200 · Karen.zhou@novotech-cro.com
Always discuss trial participation with your own doctor first.
| GenesisCare Research | Saint Leonards, New South Wales, Australia | Not Yet Recruiting |
| San Clinical Trials Unit | Wahroonga, New South Wales, Australia | Not Yet Recruiting |
| Corner Edith & Platt Streets, , NSW 2298 Australia | Waratah, New South Wales, Australia | Not Yet Recruiting |
| Hunan Cancer Hospital | Changsha, Hunan, China | Not Yet Recruiting |
| Shanghai East Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
| Henan Cancer Hospital | Zhengzhou, Zhengzhou, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07639450